FIDSON healthcare Plc (Fidson), one of Nigeria’s leading pharmaceutical manufacturers, has executed a strategic alliance with Ohara Pharmaceutical Co. Ltd (Ohara), a leading Japanese healthcare company.
This alliance is a result of Fidson’s recent Rights Issue which saw Ohara’s shareholding in the company increased to 21.57 per cent.
The strategic alliance is aimed at supporting Fidson in fulfilling its commitment to provide the Nigerian market with the latest healthcare products and services.
ALSO READ: Magu seeks collaboration with NSCDC against graft
Ohara, being a major player in the Asian pharmaceutical market, will bring cutting edge technology and innovation through technology transfer, expertise, and knowledge sharing to enhance Fidson’s excellence and ascendency in the Nigerian pharma space.
The alliance holds promise as a significant growth driver for both companies, particularly as a major factor for the development of local pharmaceutical manufacturing in Nigeria.
The significance of collaborations of this nature to the emerging Nigerian healthcare system is evidently enormous, given the rapid population growth, the healthcare state and the living standards of the larger population in the country.
Given this growing population, there is no doubt that Nigeria is in urgent need of a rapid improvement in the standard of healthcare delivery.
This can only be accelerated through modernization and technological intervention which the alliance with Ohara aims to deliver.
and then